Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM5 | P08912 | 10/20 | 0.54 |
| ▸ | CHRM1 | P11229 | 10/20 | 0.54 |
| ▸ | CHRM2 | P08172 | 8/20 | 0.54 |
| ▸ | CHRM4 | P08173 | 8/20 | 0.54 |
| ▸ | CHRM3 | P20309 | 8/20 | 0.54 |
| ▸ | MEN1 | O00255 | 2/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.50 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.46 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.44 |
| ▸ | CASP3 | P42574 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1097364 | 0.92 | CHRM5 (0.62) | CHRM5CHRM1CHRM2CHRM4CHRM3 | |
| SCHEMBL17474558 | 0.91 | CHRM5 (0.65) | CHRM5CHRM1CHRM2CHRM4CHRM3 | |
| SCHEMBL3013917 | 0.90 | CHRM5 (0.55) | CHRM5CHRM1CHRM2CHRM4CHRM3 | |
| SCHEMBL1105974 | 0.89 | CHRM5 (0.51) | CHRM5CHRM1CHRM2CHRM4CHRM3 | |
| SCHEMBL3003772 | 0.89 | CHRM5 (0.48) | CHRM5CHRM1CHRM2CHRM4CHRM3 | |
| SCHEMBL3003920 | 0.88 | CHRM5 (0.57) | CHRM5CHRM1CHRM2CHRM4CHRM3 | |
| SCHEMBL18971918 | 0.85 | MEN1 (0.47) | CHRM5CHRM1CHRM2CHRM4CHRM3 | |
| SCHEMBL3982599 | 0.85 | SLC6A3 (0.53) | CHRM5CHRM1CHRM2CHRM4CHRM3 | |
| SCHEMBL3008719 | 0.85 | MEN1 (0.46) | CHRM5CHRM1MEN1KMT2A | |
| SCHEMBL1105796 | 0.85 | MEN1 (0.50) | CHRM5CHRM1CHRM2CHRM4CHRM3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-RE49686-E1 | Nitrogen-containing heterocyclic compound and use of same | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2023-10-10 | — | — | US | disclosed |
| US-RE48334-E1 | Nitrogen-containing heterocyclic compound and use of same | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2020-12-01 | — | — | US | disclosed |
| EP-2336105-B9 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND AND USE OF SAME | TAKEDA PHARMACEUTICAL (JP) | 2014-09-17 | — | — | EP | disclosed |
| EP-2336105-B1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND AND USE OF SAME | TAKEDA PHARMACEUTICAL (JP) | 2014-02-12 | — | — | EP | disclosed |
| US-8592454-B2 | Nitrogen-containing heterocyclic compound and use of same | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-11-26 | — | — | US | disclosed |
| US-20110178060-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND AND USE OF SAME | TAKEDA PHARMACEUTICAL COMPANY LIMITED | 2011-07-21 | — | — | US | disclosed |
| EP-2336105-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND AND USE OF SAME | Takeda Pharmaceutical Company Limited (JP) | 2011-06-22 | — | — | EP | disclosed |
| US-7247641-B2 | Compounds, derivatives, compositions, preparation and uses | MGI GP, INC. (US) | 2007-07-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110178060-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND AND USE OF SAME | NTSR2, BDKRB1, AVPR1B | CHRM5 210/4885CHRM1 90/4885CHRM2 95/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.